Search

everythinglearnresearchcommunity

for

Search:↓

People are using topical melatonin for diffuse thinning and retrograde alopecia. They are discussing the best brands and application methods.

A 25-year-old male with DUPA (diffuse thinning including the donor area) has not seen improvement after 14 months on finasteride. He's considering switching to dutasteride (DUT) after advice from a hair loss YouTuber and is also contemplating trying RU58841.

A user's success in treating his diffuse and crown hair loss with finasteride and minoxidil; other users sharing their experiences, both successful and unsuccessful, and the importance of research and listening to one's body when deciding on treatments.

The user reported early stage diffuse hair thinning and increased DHT levels after 4 weeks on Finasteride and 8 weeks on Finasteride plus 4 weeks on Dutasteride, despite the medications being authentic and stored properly. They are considering increasing their Dutasteride dosage due to the lack of side effects and are unsure if the treatment is helping their hair.

A 19-year-old with diffuse hair thinning and erectile dysfunction is considering starting Propecia (finasteride) while already using a minoxidil solution with anti-androgens. Concerns are raised about the psychological nature of erectile dysfunction and the potential systemic effects of anti-androgens, with suggestions to address porn addiction and consult a doctor about hormone therapy.

A person with low-density hair likely experiencing diffuse thinning. Suggested treatments include finasteride, minoxidil, and dutasteride.

A user is starting a finasteride and minoxidil routine for diffuse pattern hair loss and is concerned about hair dependency on minoxidil. Responses suggest that new hairs may not survive without minoxidil, but existing hairs won't fall out if minoxidil is stopped, though experiences vary.

Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.

A user experienced androgenic alopecia starting at the vertex without frontal hairline recession and is seeking information on this pattern. Another user noted that vertex or diffuse hair loss is common among men.

The post discusses the experiences of individuals with diffuse hair thinning using finasteride, with many reporting no improvement or worsening conditions after 6 months. Various suggestions include persisting with the treatment, checking for underlying conditions, adding minoxidil for volume, adjusting dosage, and considering other potential causes like autoimmune responses and inflammation.

A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.

A 36-year-old experienced slow, diffuse hair thinning over 15 years and saw significant improvement using 5% topical minoxidil alone for 3 months, without finasteride or microneedling. The user is pleased with the results, noting increased hair density and no visible scalp, and plans to continue monitoring progress without using hormone-affecting treatments.

The conversation is about comparing keratin hair fibers to Gossypium Herbaceum hair fibers for diffuse hair loss. The user prefers keratin fibers for their durability and is seeking a bulk purchase option.

A 22.5-year-old male is frustrated with doctors for not taking his diffuse thinning seriously. He has been using finasteride for 2.5 years, avoids topical minoxidil due to dandruff, and is hesitant about oral minoxidil due to weight and injury concerns.

The conversation is about identifying nutritional factors that should be checked and supplemented to address diffuse hair loss, including Vitamin D, Biotin, Vitamin C, Vitamin B, Iron, Zinc, Protein, and Omega-3. No specific treatments were mentioned.

A user's progress with their hair loss treatment, which includes finasteride and nizoral, as well as the potential for using minoxidil; other users providing advice based on their own experiences; and others discussing how buzz cuts can make diffuse thinning look worse than it is.

A user has been taking finasteride for 5 months with no improvement in diffuse hair loss and suspects high levels of prolactin, cortisol, progesterone, and DHEAS, as well as iron, might be contributing to the issue. They are also taking vitamin D to address a deficiency.

A 19-year-old experiencing early hair loss started using finasteride to address diffuse thinning, despite concerns about potential side effects. They also use T/Gel and OGX Thick and Full shampoo, and have a dermatologist appointment scheduled to explore possible allergies.

The user experienced significant hair improvement with minoxidil and finasteride but later faced shedding and diffused thinning after developing seborrheic dermatitis. They are seeking advice after trying treatments like ketoconazole, coal tar shampoos, fluconazole, and hydrocortisone cream.

The user has been using 1.25 mg of oral minoxidil and finasteride since September 2025 to address diffuse hair thinning, and is considering trying a new shampoo. Other users suggest increasing the minoxidil dose and trying dutasteride.

A 22-year-old male has been using finasteride for a year and recently started oral minoxidil to address diffuse thinning and receding hair. He is considering switching to dutasteride for better results and reports healthier, thicker hair despite concerns about hairline and crown stability.

The user discusses using compounded oral minoxidil due to the ineffectiveness and inconvenience of topical minoxidil for diffuse thinning. They question the efficacy of compounded minoxidil compared to original tablet forms and express concerns about the importance of excipients and binders.

The user is experiencing hair loss with possible causes including chronic telogen effluvium, diffuse alopecia areata, and androgenic alopecia. They have tried treatments like Nizoral shampoo, minoxidil, and finasteride, and are considering a biopsy for further clarity.

A 31-year-old man using finasteride for a year is considering adding oral minoxidil or switching to topical minoxidil to address diffuse thinning, while also using a scalp massager and ketoconazole shampoo. Concerns include cardiovascular side effects, pet safety with topical minoxidil, and cost of telehealth services.

The user has been using oral finasteride and topical minoxidil for 5 years, which stopped diffuse thinning but did not improve the hairline. They are considering a hair transplant and possibly starting dutasteride.

The user is seeking a knowledgeable trichologist or dermatologist in Belgium for a thorough scalp examination due to diffuse thinning and a previous diagnosis of male pattern baldness. They are interested in procedures like a trichogram and scalp biopsy.

The user has been using finasteride (1mg daily) and oral minoxidil (2.5mg) for 2.5 years to treat diffuse thinning hair, with no side effects reported. They are satisfied with the progress, noting that the treatment has slowed hair loss and costs about £30 a month.

The user has low testosterone and DHT levels and is considering taking finasteride for Norwood 2 hair loss with diffuse thinning. They are seeking advice on whether low DHT indicates high sensitivity to DHT in the scalp and opinions on their lab values.

The user began experiencing hair loss a few years ago at age 22 and is a diffuse thinner with a Norwood scale rating of 2. They have a naturally athletic build and gain muscle easily, with a hairy chest and stomach.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.